News Related to Dementia With Lewy Bodies

CSF DOPA Decarboxylase Biomarker Shows Strong Diagnostic Potential for Lewy Body Disorders

Jun 07, 2026

A new cerebrospinal fluid biomarker for DOPA decarboxylase (DDC) shows strong diagnostic potential for Lewy body disorders including Parkinson's disease and dementia with Lewy bodies. Validated across multiple cohorts, CSF DDC levels were significantly elevated in these conditions with high diagnostic accuracy. The biomarker correlated with alpha-synuclein pathology but plasma levels showed no diagnostic value.

Experimental ALS Therapies QRL-201 and Neflamapimod Advance in Clinical Trials

May 30, 2026

Two experimental ALS therapies showed promise in recent clinical developments. Interim Phase 1/2 data suggest the antisense oligonucleotide QRL-201 restores a critical nerve protein and may slow disease decline, with a Phase 3 trial planned for 2027. Meanwhile, the oral therapy neflamapimod has been selected for testing in the UK's EXPERTS-ALS platform study, with first results expected this spring.

CervoMed's Neflamapimod Advances in DLB and ALS Clinical Programs

Apr 07, 2026

CervoMed presents new MRI data showing neflamapimod may reduce basal forebrain atrophy in dementia with Lewy bodies and finalizes Phase 3 trial design. The drug has also been selected for a UK-funded ALS platform trial, with first dosing expected by end of 2026.

DOPA Decarboxylase Biomarker Improves Diagnosis of Parkinson's and Lewy Body Dementia

Mar 25, 2026

Researchers have identified DOPA decarboxylase as a quantitative biomarker in cerebrospinal fluid that improves diagnosis of Parkinson's disease and Lewy body dementia. The protein levels are up to 2.5 times higher in affected patients and can differentiate these conditions from Alzheimer's disease. The discovery provides clinicians with an objective diagnostic tool for conditions that are frequently misdiagnosed due to overlapping symptoms.